-
Featured Authors
-
Archives
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Inside BIO Industry Analysis
13 Days Until BIO 2015: Moneyball: Acing the Big Pharma/Small Biotech Deal
In just a few weeks, thousands of players in the pharma and biotech industry will converge on Philadelphia for BIO 2015 seeking knowledge, insight and, for many, the ultimate goal – new partnerships. Collaboration is often the key to success for emerging biotech companies and big pharma alike as it can open the door to new markets, influencers and revenue streams. In oncology, deals between established pharmaceutical companies and early-stage biotechs are especially relevant and Read More >
BIO’s Dave Thomas Talks VC Funding with Daniel Levine
Last week, BIO Industry Analysis’s Dave Thomas spoke with Daniel Levine for his weekly podcast, The Bio Report. Dave discussed BIO‘s Venture Funding of Therapeutic Innovation Report, of which he is the lead author. The report analyzes data from four venture capital databases – Thomson Reuters, BioCentury, Elsevier, and Evaluate Pharm – to investigate investor trends, examine investment in specific therapeutic areas and indications, and identify disease areas that might be struggling for early-stage venture Read More >
BIO Accepting Nominations for its Award Honoring One Outstanding Woman in Industrial Biotech
Today, BIO announced that it has officially extended its deadline for the Rosalind Franklin Award for Leadership in Industrial Biotechnology. In its second year, the BIO Rosalind Franklin Award was created to honor an outstanding woman in the field of industrial biotechnology and bioprocessing. Rosalind Elsie Franklin (25 July 1920 – 16 April 1958) was a British biophysicist and X-ray crystallographer who made critical contributions to the understanding of the fine molecular structures of DNA (deoxyribonucleic acid), Read More >
Nasdaq Social Bell: Twitter Strategies For Biotechs
Last week at the BIO CEO & Investor Conference in New York City, I had the pleasure of speaking with John Machiz and Brad Smith from Nasdaq at their headquarters in Times Square to discuss the social media activity that happened onsite during the event, what made the discussion of the event online so robust, and what biotech companies can do to increase their visibility on Twitter. View the video below, and get a recap of the Read More >
Deal Structures: More Options for Companies
By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal values, , licensing values and volume were all up, as were big pharma M&A deals and asset swaps. What do these trends mean for dealmakers in 2015? Answering that question was the task of a panel at the 2015 BIO CEO & Investor Conference, Emerging Trends in Deal Structures. Moderated by Fenwick and West’s Effie Toshav, the panel included: Bruce Read More >
